semaglutide prediabetes progression to diabetes step trial Two-year effects of in adults with overweight or obesity: the 5 TrimRX | How to Track

Combination therapy remains largely experimental with limited published safety data

FOCUS ON MEDICATION: SEMAGLUTIDE AND tirzepatide Our weight loss program often includes the use of Semaglutide or Tirzepatide, especially when lifestyle changes alone arent sufficient

Improvements in access will take time, and require generation of compelling data (e.g., pharmacoeconomics, impact on comorbidities) and savvy commercial strategy

Cardiovascular Biology of the Incretin System

GLP-1 receptor agonists, including semaglutide formulations, are FDA-approved for adolescents aged 12 and older with obesity and at least one weight-related comorbidity such as type 2 diabetes or hypertension

By reducing hunger and calorie intake, GLP-1 medications allow for gradual, sustainable weight loss without the need for drastic calorie restrictions or excessive exercise